Table 2.
Contraceptive Method Discontinuation and Duration of Use During Trial Participation
| Cu-IUD n = 323 (12.5%) | Implant n = 492 (19.0%) | OCP n = 280 (10.8%) | DMPA-IM n = 1,044 (40.4%) | NET-EN n = 368 (14.2%) | None/Other Nonhormonala n = 78 (3.0%) | |
|---|---|---|---|---|---|---|
| Switched from baseline method, n (%) | 71(22.0) | 97(19.7) | 169(60.4) | 441(42.2) | 225(61.1) | 0(0.0) |
| Time to method switch (months), median (IQR)b | 9.2(5.2, 14.8) | 8.2(5.5, 12.9) | 4.0(2.0, 7.2) | 7.4(3.6, 14.7) | 7.8(3.9, 13.7) | … |
| Duration of method use (months), median (IQR)c | 16.4(9.9, 22.0) | 11.0(7.4, 18.2) | 5.6(2.8, 10.4) | 13.6(6.5, 21.2) | 11.4(5.2, 19.2) | 5.5(1.3, 16.6) |
Abbreviations: Cu-IUD, copper intrauterine device; DMPA-IM, intramuscular depot medroxyprogesterone acetate; IQR, interquartile range; NET-EN, norethisterone enanthate; OCP, oral contraceptive pill.
aAt baseline, includes only women with tubal ligation. At follow-up, includes all women using no contraceptive method or another nonhormonal contraceptive method.
bEstimated from among women who switched their baseline contraceptive method.
cEstimated from among women who used the method at any time during ASPIRE participation.